CC
CYT

Centiva Capital’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Centiva Capital’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-11,856
Closed -$45K – 2064
2022
Q1 		$45K Buy
+11,856
New +$67.5K ﹤0.01% 1433

Other funds holding CYT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Centiva Capital's CYT Position: Q2 2022 in Review

Centiva Capital sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q2 2022, closing a stake of 11,856 shares — an estimated $45K sold.

Centiva Capital first reported a position in CYT in Q1 2022 and held it in 1 quarter. The position peaked at $45K in Q1 2022. 45 funds tracked by Wall St. Rank hold CYT as of Q2 2022.

  • Centiva Capital reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Centiva Capital sold 11,856 Cyteir Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $45K.
  • Centiva Capital first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Centiva Capital's Cyteir Therapeutics, Inc. Common Stock position peaked at $45K in Q1 2022.
  • 45 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Centiva Capital's 13F filing for Q2 2022, filed 15 Aug 2022.